{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:15:11Z","timestamp":1770513311484,"version":"3.49.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%\u201330% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody\u2013drug conjugate, has demonstrated significant activity and manageable toxicities in advanced HL. Currently approved as a monotherapy for patients with HL that is relapsed or refractory to multiple lines of chemotherapy or autologous stem cell transplantation, BV is now being evaluated earlier in the course of disease and in combination with other therapies. This review discusses the successful translation of BV from its conception to the clinical setting and highlights ongoing trials that may ultimately expand its role in relapsed or refractory HL and improve outcomes for patients.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.151","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T13:39:03Z","timestamp":1416836343000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era"],"prefix":"10.1182","volume":"2014","author":[{"given":"Solomon A.","family":"Graf","sequence":"first","affiliation":[{"name":"Department of Medicine and"},{"name":"Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019111703081048700_B1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111703081048700_B2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"Durkop","year":"1992","journal-title":"Cell"},{"issue":"1","key":"2019111703081048700_B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.1992.tb04591.x","article-title":"In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence","volume":"82","author":"Falini","year":"1992","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111703081048700_B4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111703081048700_B5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clml.2012.01.012","article-title":"Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms","volume":"12","author":"Fromm","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2019111703081048700_B6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt.14.13","article-title":"Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?","volume":"6","author":"Brown","year":"2014","journal-title":"Immunotherapy"},{"issue":"19","key":"2019111703081048700_B7","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703081048700_B8","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3109\/10428194.2012.666543","article-title":"Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure","volume":"53","author":"Nathwani","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2019111703081048700_B9","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","author":"Carson","journal-title":"Cancer"},{"issue":"18","key":"2019111703081048700_B10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"key":"2019111703081048700_B11","article-title":"Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy","author":"Gopal","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111703081048700_B12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703081048700_B13","first-page":"3711","article-title":"Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [abstract]","volume":"118","author":"Forero-Torres","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703081048700_B14","first-page":"4382","article-title":"Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [abstract]","volume":"122","author":"Gopal","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111703081048700_B15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3324\/haematol.2012.083048","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials","volume":"98","author":"Zinzani","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"2019111703081048700_B16","first-page":"2743","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed\/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation [abstract]","volume":"120","author":"Rothe","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111703081048700_B17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2019111703081048700_B18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/10428194.2013.819575","article-title":"18-Fluorodeoxyglucose positron emission tomography\/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma","volume":"5","author":"Kahraman","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111703081048700_B19","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.bbmt.2013.12.168","article-title":"The Aethera trial: an ongoing phase 3 study of brentuximab vedotin in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant [abstract]","volume":"20","author":"Moskowitz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111703081048700_B20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2019111703081048700_B21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.6004\/jnccn.2011.0087","article-title":"The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma","volume":"9","author":"Holmberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"2019111703081048700_B22","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703081048700_B23","first-page":"410","article-title":"Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed\/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS\/PFS) with low transplant-related mortality (TRM) [abstract]","volume":"122","author":"Anderlini","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111703081048700_B24","article-title":"Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin's lymphoma","author":"Garciaz","journal-title":"Hematol Oncol"},{"issue":"4","key":"2019111703081048700_B25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"2019111703081048700_B26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bbmt.2011.03.010","article-title":"Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation","volume":"17","author":"Ram","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111703081048700_B27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111703081048700_B28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"120","author":"Gopal","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111703081048700_B29","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.4049\/jimmunol.173.5.2933","article-title":"CD30\/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease","volume":"173","author":"Blazar","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"2019111703081048700_B30","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2012.43.6832","article-title":"Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission","volume":"31","author":"Theurich","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111703081048700_B31","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111703081048700_B32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111703081048700_B33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2019111703081048700_B34","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703081048700_B35","first-page":"3699","article-title":"Brentuximab vedotin as first line salvage therapy in relapsed\/refractory HL [abstract]","volume":"120","author":"Chen","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703081048700_B36","first-page":"2099","article-title":"FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma [abstract]","volume":"122","author":"Moskowitz","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111703081048700_B37","first-page":"S6","article-title":"Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition","volume":"12","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"2019111703081048700_B38","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.bbmt.2013.12.257","article-title":"A phase 1\/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma in the first salvage setting: interim results [abstract]","volume":"20","author":"LaCasce","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2019111703081048700_B39","first-page":"2106","article-title":"Brentuximab vedotin administered to platinum-refractory transplant naive Hodgkin lymphoma patients can increase the proportion achieving FDG-PET negative status [abstract]","volume":"122","author":"Onishi","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111703081048700_B40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/151\/1249269\/bep00114000151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/151\/1249269\/bep00114000151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:08:30Z","timestamp":1573960110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/151\/20224\/Treatment-of-relapsed-classical-Hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.151","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}